•  
  •  
  •  
  •  

2026-08-16 04:01:33

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT

Keywords Selected:  ZimLaboratories

Stock Report

  • ZIM Laboratories Ltd receives approval from CDSCO - Directorate General of Health Services for Naproxen + Esomeprazole Capsules
  • ZIM Laboratories Limited and Globalpharma Co. L.L.C. announce strategic collaboration to Commercialize Oral Thin Film Products in the GCC Region
  • ZIM Laboratories Ltd receives Marketing Authorization for Dimethyl Fumarate (120 mg & 240 mg) Modified Release Capsules in Portugal, Europe
  • Zim Laboratories Ltd Q1 FY2025 consolidated profit at Rs. 89.83 lakhs
  • ZIM Laboratories Ltd announces grant of Marketing Authorization for Azithromycin for Oral Suspension 200 mg/5ml (40 mg/ml) in Portugal, Europe
  • Zim Laboratories Ltd reports Rs. 8.08 crores consolidated net profit in Q4 FY2024
  • ZIM Laboratories Ltd consolidated Q3 FY2023-24 net profit up QoQ at Rs. 4.78 crores
  • Zim Laboratories Ltd Q2 FY2024 consolidated PAT up QoQ at Rs. 4.14 crore
  • Zim Laboratories Ltd Q1FY24 consolidated net profit at Rs. 22.66 lakhs
  • ZIM Lab Invests in Key Partnerships in Australia and MENA
  • Zim Laboratories Ltd reports higher consolidated PAT of Rs. 7.23 crores in Q4 FY2023
  • Zim Laboratories Ltd posts higher consolidated PAT of Rs. 6.60 crores in Q3FY23
  • ZIM Laboratories Ltd allots 3,24,83,876 bonus equity shares
  • ZIM Laboratories Limited lists on the National Stock Exchange
  • ZIM Laboratories Limited to list on NSE on 25th November, 2022
  • ZIM Laboratories Ltd posts consolidated net profit of Rs. 5.14 crores in Q1FY23
  • Zim Laboratories consolidated Q4 FY2022 net profit soars to Rs. 7.03 crores
  • ZIM Laboratories Ltd receives Marketing Authorization for Sildenafil 50 mg Orally Dissolving Film in Spain, Europe
  • Zim Laboratories posts consolidated PAT of Rs. 4.07 crore in Q3FY22
  • Zim Laboratories Ltd posts consolidated PAT of Rs. 3.25 crore in Q2FY22

Latest Post

  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025